Monday, 13 January 2020
Exonate Ltd has secured a major collaboration deal with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson for its ophthalmology program.
Exonate has been developing a revolutionary new treatment for leading causes of blindness (diabetic retinopathy and age related macular degeneration).
Exonate Ltd was spun out of the University of Nottingham in 2013 by University of Nottingham academics, Prof David Bates and Prof Lucy Donaldson and Professor Steven Harper from the University of Bristol based on their intellectual property along with that of University of New South Wales’ Professor Jonathan Morris.
Through the collaboration, Exonate will work with Janssen Research & Development, and LLC scientists to develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
Scientists at Exonate have developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. The agreement was facilitated by Johnson & Johnson Innovation.
The collaboration will fund the clinical trial and other activities in the company that will enable development of the first eye drop for treatment of diabetic macular oedema initially. The approach could transform the treatment of neovascular eye diseases, a market currently worth more than $6Bn a year, and extend it to preventative care too.
Exonate’s CEO, Dr Catherine Beech said “I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases”
This collaboration agreement allows Exonate to reach its primary goal of testing its designer compounds in patients for the first time. Over the last six years the team have worked immensely hard to develop key molecules that have the right safety, efficacy and delivery properties to be highly promising for patients. We will now be able to take that right through to clinical trial and beyond, in collaboration with one of the world’s largest pharmaceutical companies.”
More information is available from Professor David Bates at firstname.lastname@example.org
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email
email@example.com or see the
Globelynx website for how to register for this service.
For up to the minute media alerts,
follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the
world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named both Sports and International University of the Year in the 2019 Times and Sunday Times Good University Guide, was awarded gold in the
TEF 2017 and features in the top 25 of all
three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to
REF 2014. We have
six beacons of research excellence helping to transform lives and change the world; we are also a major employer, proud of our Athena SWAN silver award, and a key industry partner- locally and globally.